Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine in chronic heart failure (SHIFT)
NCT02441218Phase 3Completed
- Sponsor
- Servier
- Start
- Sep 2006
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of ivabradine in chronic heart failure (CHF), sponsored by Servier. Primary endpoint: Cardiovascular Death or Hospitalization for Worsening Heart Failure at 42 months. Started Sep 2006; status: completed.
02
Drugs
ivabradine
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT02441218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441218.